ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2025
Comorbidities among American Indian and Alaska Native People with Cancer: A Surveillance, Epidemiology, and End Results-Medicare Study.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundComorbidities may affect the incidence and management of cancers. The burden of comorbidities among American Indian and Alaska Native (AIAN) patients with cancer and survivors is unknown.
methodsUsing Surveillance, Epidemiology, and End Results-Medicare, we identified AIAN people aged ≥66 years diagnosed with female breast, lung, and colorectal cancers (2000-2019), with at least 1 year of Medicare coverage prior to diagnosis. We used latent class analysis (LCA) to identify comorbidity profiles and multinomial logistic regression to examine associations of class membership with sociodemographic characteristics.
resultsThe mean NCI weighted comorbidity index was 0.53 (±0.59) for those with breast cancer, 0.59 (±0.65) for those with colorectal cancer, and 0.76 (±0.68) for those with lung cancer. For breast and colorectal cancers, LCA identified three classes (low, medium, and high comorbidities). For lung cancer, LCA identified four classes (two "medium" comorbidity classes differed in the proportion of chronic obstructive pulmonary disease and cardiovascular-related diseases). Sex, age, residence in a purchased/referred care delivery area, and year of diagnosis were associated with class membership for each cancer. Colorectal cancer class membership was associated with the proportion of the population with limited access to a grocery store; lung cancer class membership was associated with the proportion of the AIAN population with limited fluency in the English language.
conclusionsThe NCI comorbidity score among AIAN people with cancer was slightly higher than published reports for those of non-Hispanic Whites. IMPACT: Managing comorbidities and cancer treatment may be complicated for AIAN people due to the provision of noncancer care within the Indian Health Service and the need to coordinate across multiple care systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.